Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Viridian Therapeutics (VRDN – Research Report). The associated price target remains the same with $46.00.
Rami Katkhuda’s rating is based on several promising developments within Viridian Therapeutics. The company reported strong financials with $636.6 million in cash and equivalents, which is expected to sustain operations until the second half of 2027. This financial stability provides a solid foundation for continued research and development efforts.
Furthermore, Viridian’s pipeline shows significant potential, particularly with the drug veligrotug, which is on track for a Biologics License Application in the second half of 2025. The clinical data suggests that veligrotug offers advantages over current treatments for thyroid eye disease (TED), such as faster efficacy onset and benefits for chronic TED patients. Additionally, the VRDN-003 program is progressing well, with pivotal trial results expected in the first half of 2026. These factors collectively indicate a strong potential for Viridian to capture a substantial market share in the TED space, justifying the Buy rating.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 17.1% and a 39.63% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., VYNE Therapeutics, and Inventiva.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $41.00 price target.